Drug Trial Radar · NCT03459534
A Phase 3 Study for the Efficacy and Safety of Radotinib in CP-CML Patients With Failure or Intolerance to Previous TKIs
Last checked: Nov 19, 2026Latest source record: Sep 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
173
Planned (sponsor's estimate)
Start
Jun 25, 2018
Primary completion
Jun 30, 2027
Study completion Jun 30, 2028
Sponsor
- Lead sponsor
- Il-Yang Pharm. Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Mar 9, 2018
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
In a multinational, multicenter, single-arm, open-label and Phase III Radotinib clinical study, chronic phase Ph+ chronic myeloid leukemia patients with failure or intolerance to previous TKIs therapy including Imatinib will be recruited. In this phase 3 study, 173 subjects are expected to be enrolled in a single arm with the administration of Radotinib 400mg twice daily, which includes 10% of dropout rate.
Conditions
- Chronic Myeloid Leukemia, Chronic Phase
- CML, Chronic Phase
- CML, Refractory
- CML - Philadelphia Chromosome
Interventions
Radotinib HClDrug
1. Brand name/manufacturer: Supect Cap./IL-YANG PHARM. Co., Ltd. 2. Active ingredient: radotinib HCl 106.8mg (100mg as radotinib) or HCl 213.6mg (200mg as radotinib) 3. Appearance and formulation: hard capsule with a light blue cap and a body containing pale yellow powder 4. Storage conditions: Store in an airtight light proof container at room temperature.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Major Cytogenetic Response (MCyR)Time frame: at month 6
Locations
18 sites in 4 countries. Site status is shown where the registry gives one.
Territorial State Budgetary Institution
Barnaul, Russia · Not yet recruiting
Federal State Budgetary Institution of Science
Kirov, Russia · Recruiting
Federal State Budgetary Institution
Moscow, Russia · Not yet recruiting
Hematology Centre based on City Clin. Hosp. n.a. S.P. Botkin
Moscow, Russia · Recruiting
Federal State Budgetary Institution
Saint Petersburg, Russia · Recruiting
Federal State Budgetary Institution
Saint Petersburg, Russia · Recruiting
Uijeongbu Eulji Medical Center, Eulji University
Uijeongbu-si, Gyeonggi-do, South Korea · Recruiting
Ankara University Medical Faculty
Ankara, Turkey (Türkiye) · Recruiting
Gazi University Medical Faculty
Ankara, Turkey (Türkiye) · Recruiting
Istanbul University Cerrahpasa - Cerrahpasa Medical Faculty
Istanbul, Turkey (Türkiye) · Recruiting
Ege University Medical Faculty
Izmir, Turkey (Türkiye) · Recruiting
Mersin University Medical Faculty
Mersin, Turkey (Türkiye) · Recruiting
Ondokuz Mayis Univ. Med. Fac.
Samsun, Turkey (Türkiye) · Recruiting
CI Cherkasy Regional Oncological Dispensary of CRC
Cherkassy, Ukraine · Recruiting
CTPI Chernihiv Regional Oncological Dispensary
Chernihiv, Ukraine · Recruiting
CI Dnipropetrovsk CMCH #4 OF Dnipropetrovsk RC
Dnipro, Ukraine · Recruiting
Institute of CR of SI NSC of Radiation Medicine of NAMSU H&T Unit
Kyiv, Ukraine · Recruiting
SI Institute of Blood Pathology and Transfusion Medicine of AMSU
Lviv, Ukraine · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.